anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIS is characterized by a lateral curvature of the spine greater than 10 degrees plus rotation of the spinal vertebrae. AIS is found in adolescents between the age of 10 and time of skeletal maturity. Progression of a spinal curve to 50 degrees suggests a high risk for continued curve progression throughout adulthood and usually indicates the need for spinal fusion surgery. Only about 10 percent of adolescents with AIS end up having curves that progress and require surgical intervention. While certain risk factors for curve progression have been identified, there is no reliable way of estimating the likelihood of needing surgery. Bracing is currently the standard of care for treating AIS. However, the effectiveness of bracing remains unclear, and it is unknown which adolescents in particular may benefit from bracing. Therefore, adolescents undergo bracing without knowing their likelihood of avoiding surgery. The purpose of this study is to compare the risk of curve progression in adolescents with AIS who wear a brace versus those who do not and to determine whether there are reliable factors that can predict the usefulness of bracing for a particular individual with AIS. The study will also evaluate the best dosing and duration schedule and how bracing affects quality of life, functioning, and psychosocial adjustment among participants.

Participation in this study will last until a participant reaches skeletal maturity or their spinal curve progresses to 50 degrees, after which usual care will continue. Participants will either be 1)randomly assigned to a treatment or 2) may decline randomization and choose their own treatment arm. Study visits will occur every 6 months at an orthopaedic surgeon's office and will include x-rays, a clinical exam, and questionnaires. Participants assigned to braces will be instructed to wear the brace at least 18 hours per day. Temperature monitors placed in the brace will be used to determine the actual wear time by each participant.
Treatment with metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose. An analysis of utilization of patterns showed that about 20% of patients who used metoclopramide took it longer than 12 weeks. Treatment with metoclopramide for longer than the recommended 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD. 

Although the risk of developing TD in the general population may be increased among the elderly, women, and diabetics, it is not possible to predict which patients will develop metoclopramide-induced TD. Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose. 

Metoclopramide should be discontinued in patients who develop signs and symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients, TD may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn. 

Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Therefore, metoclopramide should not be used for the symptomatic control of TD.
Most in situ tissue-engineered heart valve (TEHV) evaluation studies are conducted in a healthy physical environment, which cannot accurately reflect the specific characteristics of patients. In this study, we established a diabetic rabbit model and implanted decellularized extracellular matrix (dECM) into the abdominal aorta of rabbits through interventional surgery with a follow-up period of 8 weeks. The results indicated that dECM implants in diabetic rabbits exhibited poorer endothelialization and more severe fibrosis compared to those in healthy animals. Furthermore, mechanistic studies revealed that high glucose induced endothelial cell (EC) apoptosis and impeded their proliferation and migration, accompanied by an increase in reactive oxygen species (ROS) concentration and a decrease in the nitric oxide (NO) level. High glucose also led to elevated ROS levels and an increased expression of inflammatory factors and transforming growth factor β1 (TGF-β1) in macrophages, contributing to fibrosis. These findings suggest that oxidative-stress-mediated mechanisms are likely the primary pathways affecting heart valve repair and regeneration under diabetic conditions. Therefore, future design and evaluation of TEHVs may concern more patient-specific circumstances.
The invention belongs to the fields of medicines and genetic engineering and relates to an Epigallocatechin gallate (ECG) and daunorubicin (DNR) composition and use thereof. The invention provides a tumor cell proliferation inhibiting composition which contains the Epigallocatechin gallate (ECG) and daunorubicin. When the composition is used for preparing anti-tumor medicines, the heart toxicity of DNR can be lowered greatly, the anti-tumor effect of the DNR can be improved greatly and the dosage of DNR and medicine cost can be reduced relatively. The ECG is natural extract of tea leaves which is a common drink for two thirds of world population. Therefore, the resource is rich, the price is low, and toxic effect hardly appears in thousands of years of drinking. EGC is used as an assistant medicine of DNR. In the invention, the formula scheme of a high-efficiency and low-price antitumor medicine is provided, the tumor inhibition efficiency is improved, and the treatment cost of patients with tumor is reduced.
PURPOSE: A cosmetic composition containing extract of immature Torreya nucifera fruit or seed is provided to ensure antioxidation, antiaging, and whitening. CONSTITUTION: A cosmetic composition contains 0.01-10 weight% of immature Torreya nucifera fruit and seed extract as an active ingredient. The immature Torreya nucifera fruit or seed is collected during June to September. The cosmetic composition is used for antioxidation, antiaging, whitening, or anti-wrinkling. The extract is isolated using water or organic solvent. The organic solvent is ethanol, methanol, butanol, hexane, ether, ethyl acetate, chloroform, or mixture of the organic solvent and water.
The invention discloses that the ethanol extract of thick vine leaves has good inhibition effect on dengue virus. Accordingly, the inventor also establishes a corresponding preparation method of the extract. Experiments show that the ethanol extract of the thick vine leaves has the effect of resisting dengue virus. After fractionation, the fourth fraction and the fifth fraction both showed anti-dengue virus effect, wherein the fifth fraction showed increased antiviral effect with increasing dosing concentration, which was against dengue virus IC 50 It was 2.64. mu.g/ml. Therefore, the thick vine has potential value of anti-dengue virus drugs. Therefore, the invention provides powerful basis and reliable guarantee for further opening up the medical application of the traditional Chinese medicine pachyrhizus and opens up a Chinese herbal medicine approach for treating dengue fever.
Peripheral T-cell Lymphoma (PTCL) is a heterogenic malignancy with poor outcome. Five-year PFS (progression-free survival) and OS (overall survival) for these patients received classic CHOP regimen is less than 30%. High-dose intensive chemotherapy doesn't demonstrate better response. At present, there is no standardized treatment protocol for this kind of lymphoma. So, clinical trials are encouraged by NCCN for those patients.

For the less efficacy of CHOP or CHOP-like regimen, multi-drug combination strategy has been the therapy tendency in PTCL. Zhang et al, reported that GDP compared with CHOP as the therapy strategy for PTCL-NOS (Not Otherwise Specified). The response rate was 78.57% in GDP group and 60.00% in CHOP group, respectively. DFS (disease-free survival) was 9.79 and 4.2 months in above two groups. They concluded that GDP is superior to CHOP. The main side-effect of two regimens is hematological toxicity. Combination with etoposide can improve the outcome of some patients with high risk factors. Furthermore, high-dose combined with ASCT (autologous stem cell transplantation) has been the first-line therapy for PTCL. Some refractory/relapsed patients with PTCL will benefit from allogeneic bone marrow transplantation. However, about 30% patients with PTCL have no chance to receive ASCT for multiple reasons. So, it is urgent to explore new combination-therapy regimen to improve the outcome for patients with PTCL.

The aim of our study is to compare the response and survival rate of GDPE/CEOPE (gemcitabine, cis-platinum, etoposide, and dexamethasone/cyclophosphamide, vincristine, pharmorubicin, etoposide, and prednisone) with those of CEOPE (/cyclophosphamide, vincristine, pharmorubicin, etoposide, and prednisone ) regimen, looking forward to its superiority in efficacy and safety for the newly diagnosed adult patients with PTCL.
There is disclosed an improved method for separating one of alpha-1-proteinase inhibitor (also known as alpha-1 antitrypsin) and antithrombin-III from an aqueous solution of plasma proteins containing the same, such as from Cohn Fraction IV-1, Cohn Fraction IV, reworks of Cohn Fraction IV and IV-1, Cohn Effluent II & III and Cohn Effluent I. The method includes the steps of first holding an aqueous solution of plasma proteins containing one of alpha-1-proteinase inhibitor and antithrombin-III in a relatively large volume of buffer solution as solvent and at a pH adjusted to be relatively basic when compared to conditions heretofore known, and at a temperature in the range of from 2°-50° C. for a period of about 0.2-24 hours. Following the above treatment, alpha-1-proteinase inhibitor and antithrombin-III are obtained by applying conventional techniques to the resulting solution. Accordingly, the solution is then mixed with a polyalkylene glycol, e.g. polyethylene glycol, in the range of from as low as 8% to as high as 23% (w/v) based on volume of solution to selectively precipitate unwanted proteins. The alpha-1-proteinase inhibitor is then separated from the supernatant solution by adsorption on an anion exchange resin or by precipitation by further addition of a polyalkylene glycol, e.g. polyethylene glycol. The method of the invention provides an improvement in the yield of alpha-1-proteinase inhibitor.
BACKGROUND: Heart Rate Variability (HRV) is a dynamic reflection of heart rhythm regulation by various physiological inputs. HRV deviations have been found to correlate with clinical outcomes in patients under physiological stresses. Perioperative cardiovascular complications occur in up to 5% of adult patients undergoing abdominal surgery and are associated with significantly increased mortality. This pilot study aimed to develop a predictive model for post-operative cardiovascular complications using HRV parameters for early risk stratification and aid post-operative clinical decision-making.
METHODS: Adult patients admitted to High Dependency Units after elective major abdominal surgery were recruited. The primary composite outcome was defined as cardiovascular complications within 7 days post-operatively. ECG monitoring for HRV parameters was conducted at three time points (pre-operative, immediately post-operative, and post-operative day 1) and analyzed based on outcome group and time interactions. Candidate HRV predictors were included in a multivariable logistic regression analysis incorporating a stepwise selection algorithm.
RESULTS: 89 patients were included in the analysis, with 8 experiencing cardiovascular complications. Three HRV parameters, when measured immediately post-operatively and composited with patient age, provided the basis for a predictive model with AUC of 0.980 (95% CI: 0.953, 1.00). The negative predictive value was 1.00 at a statistically optimal predicted probability cut-off point of 0.16.
CONCLUSION: Our model holds potential for accelerating clinical decision-making and aiding in patient triaging post-operatively, using easily acquired HRV parameters. Risk stratification with our model may enable safe early step-down care in patients assessed to have a low risk profile of post-operative cardiovascular complications.
The invention relates to application of intestinal flora regulation of dipsacus asperoides VI in osteoporosis medicines. The dipsacus asperoides VI are used as the main active ingredients of the Chinese herbal medicine dipsacus asperoides and have good pharmacological activity. The invention explores the effect of dipsacus asperoides saponin VI in regulating intestinal flora, and the intestinal flora disorder is one of the important causes for inducing osteoporosis, so the exploration of the effect of dipsacus asperoides saponin VI in regulating intestinal flora has wide development prospect in the development of osteoporosis medicines. Research results show that the dipsacoside VI can improve bone microenvironment by regulating intestinal flora and metabolites thereof, so as to inhibit disuse osteoporosis. The dipsacoside VI plays an important role in the balance of bone metabolism by influencing the regulation of the 5-HT pathway by specific flora and metabolites thereof. The novel mechanism is provided for the asperosaponin VI to resist osteoporosis, and a novel visual angle is provided for the research and development of osteoporosis inhibiting medicines.
The invention belongs to the technical field of material preparation, and particularly relates to a preparation method of an ionic strength immune magnetic fluorescent micro motor. Most of the existing chemical driving micro-nano motors utilize metal catalysts to decompose hydrogen peroxide to generate chemical energy to drive the motors. The hydrogen peroxide has biotoxicity, so that the hydrogen peroxide is not suitable for the biomedical field in most application scenes, particularly when the hydrogen peroxide is involved. A second disadvantage of chemically driven motors is non-ionic immunity. With the increase of the ionic strength, the movement activity of the chemical driving motor is greatly reduced, the movement capability is greatly weakened, and the motor basically does not move in the ionic strength environment close to human body fluid. A third disadvantage is that the movement time of the chemical drive motor movement is very short. The magnetic fluorescent micron motor prepared by the method has the outstanding advantages of no biotoxicity, ionic strength immunity, infinite movement time and the like, has huge application prospects in the fields of biomedicine and the like, and is expected to fill the blank of the field and realize large-scale practicability of the micro-nano motor in the field of biomedicine.
Compounds isolated from plant materials, particularly plants of the genus Vaccinium, which have biological activity measurable as inhibition with adhesion of bacterial cells to surfaces, and an extract of such plant materials which is significantly enriched for the anti-adhesion activity. The specific compounds include procyanidins (also known as “condensed tannins”), leukocyanin, leucodelphinin, flavonol glucosides including myricetin-3-pyranoside and proanthocyanidin extracts. These proanthocyanidin extracts are capable of inhibiting agglutination reactions of P-type  E. coli.  The extracts containing proanthocyanidins contain at least one A-type interflavanoid bond. Methods of making an extract. Methods of preventing or treating urogenital infections in a mammal by administering a proanthocyanidin composition including the proanthocyanidin extract, a proanthocyanidin compound, a proanthocyanidin polymer or a mixture thereof, to a subjecct in an amount and for a time sufficient to prevent, reduce or eliminate symptoms associated with such infections.
In the short-term controlled trials of lacosamide in adult patients with partial-onset seizures with no significant system illnesses, there was no increase in syncope compared to placebo. In the short-term controlled trials in adult patients with diabetic neuropathy, for which lacosamide is not indicated, 1.2% of patients who were treated with lacosamide reported an adverse reaction of syncope or loss of consciousness, compared with 0% of placebo- treated patients with diabetic neuropathy. Most of the cases of syncope were observed in patients receiving doses above 400 mg/day. The cause of syncope was not determined in most cases. However, several were associated with either changes in orthostatic blood pressure, atrial flutter/fibrillation (and associated tachycardia), or bradycardia. Cases of syncope have also been observed in open-label clinical partial-onset seizure studies in adult and pediatric patients. These cases were associated with a history of risk factors for cardiac disease and the use of drugs that slow AV conduction.
PURPOSE:To obtain a new antitumor substance BE-34776 or its pharmacologically permissible salt having antitumor action and exhibiting excellent antitumor effect on various tumors on which sufficient effect cannot be attained by the use of conventional antitumor substances. CONSTITUTION:The antitumor substance BE-34776 expressed by the formula or its pharmacologically permissible salt. The compound of the formula or its salt can be produced by culturing a microbial strain belonging to the genus Micromonospora and capable of producing the antitumor substance BE-34776, separating the antitumor substance BE-34776 from the cultured product and optionally converting to its pharmacologically permissible salt. The preferable strain to be used in this process is Micromonospora sp. A-34776 (FERM P-13396) collected in Noumea, New Caledonia or its mutant. The compound of the formula is especially useful as an antitumor agent.
Heart failure with preserved ejection fraction (HFpEF) is associated with severe morbidtiy and mortality. Yet, little is known about factors leading to the development of HFpEF investigated in a longitudinal fashion. The PREDICT-HFpEF study aims to adress this open question. Patients that were initially included in a large cohort study (LIFE-Heart study) approximately 7-years ago, that underwent thorough clinical, laboratory and echocardiographic assessment, and did not show evidence of heart failure at the present time point will be included in the current study.

Patients will be screened for the development of HFpEF or other forms of heart failure (e.g. heart failure with reduced ejection fraction) and will again undergo thorough clinical, laboratory and echocardiographic assessment. Initially measured biomarkers (including clinical data, lab-charts, ECG recordings and echocardiography) will be used to predict the development of HFpEF in this cohort at cardiovascular risk.
Gout is the most common form of inflammatory arthritis worldwide and is characterized by painful recurrent flares of inflammatory arthritis that are associated with a transiently increased risk of adverse cardiovascular events. Furthermore, gout is associated with multiple cardiometabolic-renal comorbidities such as type 2 diabetes, chronic kidney disease and cardiovascular disease. These comorbidities, potentially combined with gout flare-related inflammation, contribute to persistent premature mortality in gout, independently of serum urate concentrations and traditional cardiovascular risk factors. Although better implementation of standard gout care could improve gout outcomes, deliberate efforts to address the cardiovascular risk in patients with gout are likely to be required to reduce mortality. Sodium-glucose cotransporter type 2 (SGLT2) inhibitors are approved for multiple indications owing to their ability to lower the risk of all-cause and cardiovascular death, hospitalizations for heart failure and chronic kidney disease progression, making them an attractive treatment option for gout. These medications have also been shown to lower serum urate concentrations, the causal culprit in gout risk, and are associated with a reduced risk of incident and recurrent gout, potentially owing to their purported anti-inflammatory effects. Thus, SGLT2 inhibition could simultaneously address both the symptoms of gout and its comorbidities.
BACKGROUND: Surgical site infections (SSIs) are among the most common postoperative complications. Glioblastoma multiforme is the most frequent malignant brain tumor with a dismal prognosis despite combined treatment. The effect of SSIs on the course of glioblastoma patients has not been fully clarified since available data are limited and partially contradictory. The aim of this study is to investigate the impact of SSIs on the course of patients with glioblastoma.
METHODS: The medical records of all patients undergoing surgery for glioblastoma between 2010 and 2020 in our institution were scanned and those with surgical site infections after glioblastoma resection were identified and compared to an age-matched control group. Overall survival and progression-free survival were the primary endpoints followed by the number of hospitalizations and the length of stay in hospital.
RESULTS: Out of 305 patients undergoing surgery for glioblastoma, 38 patients with postoperative surgical site infection after resection were identified and 15 (5 men and 10 women aged between 9 and 72) were included in this study. 23 patients were excluded. The control group consisted of 30 age-matched patients without SSI (18 men and 12 women). There were no significant differences in median overall survival. Progression-free survival was higher in the SSI group. The number of hospitalizations and the length of stay were significantly higher in the SSI group.
CONCLUSION: Our data suggest that SSIs might reduce early recurrences without affecting overall survival. Furthermore, they might decrease health-related quality of life by doubling the total length of hospital stay.
PCT No. PCT/AU95/00613 Sec. 371 Date Jun. 17, 1997 Sec. 102(e) Date Jun. 17, 1997 PCT Filed Sep. 18, 1995 PCT Pub. No. WO96/08261 PCT Pub. Date Mar. 21, 1996A probiotic composition is disclosed which is particularly useful for inclusion in food products to enhance their nutritional value. The composition comprises one or more probiotic microorganisms such as Bifidobacterium and a carrier to transport the microorganisms to the large bowel or other regions of the gastrointestinal tract. The carrier is a modified or unmodified resistant starch, particularly a high amylose starch, which acts as a growth or maintenance medium for microorganisms in the large bowel or other regions of the gastrointestinal tact.